New drug tested to help kidney transplants last
NCT ID NCT06365437
Summary
This study tested a new drug, TCD601, to see if it is safe and works as well as the standard drug (rATG) to prevent a patient's body from rejecting a new kidney after transplant. It involved 33 adults who received a kidney from a donor. The main goal was to check for side effects and see how the drug behaves in the body over 12 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hospital Clinic de Barcelona
Barcelona, 08036, Spain
-
Hospital Universitari de Bellvitge
Barcelona, 08907, Spain
-
Innsbruck Medical University
Innsbruck, A-6020, Austria
-
Karolinska University Hospital
Stockholm, Huddinge, 14157, Sweden
-
Sahlgrenska University Hospital
Gothenburg, 41345, Sweden
-
Skåne University Hospital
Malmo, 20502, Sweden
-
University of Vienna
Vienna, 1090, Austria
Conditions
Explore the condition pages connected to this study.